Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer

Annals of Oncology

Volumn 26, Issue 12, 2015, Pages 2503-

  Schirripa, M ^a,b   Loupakis, F ^a,b   Lonardi, S ^c   Cremolini, C ^a,b   Bergamo, F ^c   Zagonel, V ^c   Falcone, A ^a,b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADVERSE OUTCOME; ARTICLE; CLINICAL STUDY; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; LIFE EXPECTANCY; METASTASIS; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; TREATMENT RESPONSE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MUTATION; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; MUTATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84949991071     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv385     Document Type: Letter

References (3)

1. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-1820.
2. Tejpar S, Celik I, Schlichting M et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-3577.
3. Kumar SS, Price TJ, Mohyieldin O et al. KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointest Cancer Res 2014; 7: 23-26.